ananyo writes "A court decision on 23 July could help to tame the largely unregulated field of adult stem-cell treatments. The US District Court in Washington DC affirmed the right of the Food and Drug Administration (FDA) to regulate therapies made from a patient's own processed stem cells. The case hinged on whether the court agreed with the FDA that such stem cells are drugs. The judge concurred, upholding an injunction brought by the FDA against Regenerative Sciences, based in Broomfield, Colorado. The FDA had ordered Regenerative Sciences to stop offering 'Regenexx', its stem cell treatment for joint pain, in August 2010. As Slashdot has noted before, they are far from the only company offering unproven stem cell therapies."

An anonymous reader writes "Researchers reporting online on July 26 in Current Biology have for the first time shown that they can control the behavior of monkeys by using pulses of blue light to very specifically activate particular brain cells (abstract). The findings represent a key advance for optogenetics, a state-of-the-art method for making causal connections between brain activity and behavior. Based on the discovery, the researchers say that similar light-based mind control could likely also be made to work in humans for therapeutic ends."

Maximum Prophet writes "If you've ever had your eyes scanned, be sure to install new ones every 90 days. Wired reports on research being released at Black Hat: 'The replica images, they say, can trick commercial iris-recognition systems into believing they’re real images and could help someone thwart identification at border crossings or gain entry to secure facilities protected by biometric systems. The work goes a step beyond previous work on iris-recognition systems. Previously, researchers have been able to create wholly synthetic iris images that had all of the characteristics of real iris images — but weren’t connected to real people. The images were able to trick iris-recognition systems into thinking they were real irises, though they couldn’t be used to impersonate a real person. But this is the first time anyone has essentially reverse-engineered iris codes to create iris images that closely match the eye images of real subjects, creating the possibility of stealing someone’s identity through their iris.'"

ananyo writes "The first competitor has swaggered up to the starting line for a contest that aims to push the limits of genome-sequencing technology. The X Prize Foundation of Playa Vista, California, is offering a US$10 million prize to the first team to accurately sequence the genomes of 100 people aged 100 or older, for $1,000 or less apiece and within 30 days. Ion Torrent, part of Life Technologies of Carlsbad, California, believes that its semiconductor-based technology gives it a shot, and on 23 July it announced that it will compete. The Archon Genomics X Prize competition, to be held in September 2013, is intended to spur technology, boost accuracy and drive down costs — currently $3,000–5,000 per genome. Peter Diamandis, the X Prize Foundation's chief executive, says that the contest will help to establish a standard for a 'medical grade' genome, with the high accuracy needed to diagnose or treat a patient. This time, the X prize Foundation has relaxed the time frame, allowing competitors 30 days — rather than the 10 specified by the 2006 contest — and focused on centenarians, who might carry gene variants promoting longevity. The winning team will be the first to sequence all 100 genomes to 98% completion, with less than one error per million base pairs, and to determine which variants appear on which of the paired chromosomes."

An anonymous reader writes "The inaugural G-Prize contest, conceived and exclusively sponsored by Gen9, was launched to foster creative and innovative approaches for using synthetic DNA libraries to constructively advance industries such as pharmaceuticals, chemicals, biofuels and agriculture. Winners of the inaugural G-Prize will receive a free library of up to 500 GeneBits DNA constructs. Each GeneBits construct is a double-stranded gene fragment from 500 to 1,024 base-pairs in length, with error rates better than 1:2,500."

Diggester writes "While Americans worry every year about getting a flu shot or preventing HIV/AIDS, the deadlier silent killer is actually Hepatitis C, killing over 15,000 people yearly in the U.S. since 2007 — and the numbers continue to increase as the carriers increase in age. While there is no vaccine, there is hope in nanoparticle technology. The breakthrough came from a group of researchers at the University of Florida, creating a 'nanozyme' that eliminates the Hep C 100% of the time; before now, the six-month treatment would only work about half the time. The particles are coated with two biological agents, the identifier and the destroyer; the identifier recognizes the virus and sends the destroyer off to eliminate the mRNA which allows Hep C to replicate." Reader Joiseybill adds a link to coverage in the IEEE Spectrum, and points out that the 100 percent success rate, while encouraging, is so far only in the lab.

ananyo writes "Bioengineers have made an artificial jellyfish using silicone and muscle cells from a rat's heart. The synthetic creature, dubbed a medusoid, looks like a flower with eight petals. When placed in an electric field, it pulses and swims exactly like its living counterpart. The team now plans to build a medusoid using human heart cells. The researchers have filed a patent to use their design, or something similar, as a platform for testing drugs (abstract). 'You've got a heart drug?' says Kit Parker, a biophysicist at Harvard University in Cambridge, Massachusetts, who led the work. 'You let me put it on my jellyfish, and I'll tell you if it can improve the pumping.'" The video that accompanies the text is at once beautiful and creepy.

another random user writes "According to the BBC, 'Europe is on the cusp of approving a gene therapy for the first time, in what would be a landmark moment for the field. ... The European Medicines Agency has recommended a therapy for a rare genetic disease which leaves people unable to properly digest fats. The European Commission will now make the final decision. The idea of gene therapy is simple: if there is a problem with part of a patient's genetic code then replace that part of the code. The reality has not been so easy. In one gene therapy trial a U.S. teenager, Jesse Gelsinger, died, and other patients have developed leukaemia. There no gene therapies available outside of a research lab in Europe or the U.S.' They have considered the use of Glybera to treat lipoprotein lipase deficiency, which leads to fat building up in the blood, abdominal pain and life-threatening pancreatitis (inflammation of the pancreas). 'The therapy uses a virus to infect muscle cells with a working copy of the gene.'"

dstates writes "An industry has grown up around patents guaranteeing exclusive access to testing of mutations in specific genes, but recently the Supreme Court rejected a biotechnology patent saying laws of nature cannot be patented, and threw the issue of patents on genes back to the lower courts. The Court of Appeals is now preparing to hear arguments on whether genes can be patented. The results will have major implications. On the one hand, restricting access to whole regions of the human genome will stifle scientific progress. On the other, companies like Myriad Genetics and Optimal Medicine use the patents to protect years of work invested in research, but this also means preventing other companies from offering diagnostics based on competing faster and lower cost technologies to analyze mutations in these genes."

ananyo writes "With the Olympics due to kick off on 27 July in London, Nature has taken a look at how far science would be able to push human athletic abilities if all restrictions on doping were lifted. The article mentions anabolic steroids (up to 38% increase in strength), IGF-1 (4% increase in sprinting capacity), EPO/blood doping (34% increase in stamina), gene doping and various drugs and supplements, as well as more 'extreme' measures such as surgery and prosthesis. Hugh Herr, a biomechanical engineer at MIT, says performance-enhancing technologies will one day demand an Olympics all their own. But is that time already upon us?"

First time accepted submitter rosy rohangi writes "Biologists at UC San Diego have discovered a chemical that provides a completely new direction and promise for the development of drugs to treat metabolic disorders such as type 2 diabetes – a key concern of public health in the U.S. due to the current obesity epidemic. From the article: '...Scientists have long suspected that diabetes and obesity could be related to problems of the biological clock. Laboratory mice with altered biological clocks, for example, often become obese and develop diabetes. Two years ago, a team led by Steve Kay, dean of the Division of Biological Sciences at UC San Diego, discovered the first biochemical link between the biological clock and diabetes. He found that a key protein, cryptochrome, which regulates the biological clocks of plants, insects and mammals also regulates glucose production in the liver and that changes in levels of this protein could improve the health of diabetic mice.'"

stoilis sends this quote from an article at Science: "Vaccines aren't supposed to cause disease. But that appears to be what's happening on Australian farms. Scientists have found that two virus strains used to vaccinate chickens there may have recombined to form a virus that is sickening and killing the animals 'This shows that recombination of such strains can happen and people need to think about it,' says Glenn Browning, a veterinary microbiologist at the University of Melbourne, Parkville, in Australia and one of the co-authors on the paper."

An anonymous reader writes with news that researchers at the Georgia Institute of Technology have taken a gene from 500-million-year-old bacteria and inserted it into modern E. coli bacteria. They then allowed the bacteria to evolve over the course of a thousand generations to see whether it would resemble its original 'evolutionary trajectory.' From the article: "After achieving the difficult task of placing the ancient gene in the correct chromosomal order and position in place of the modern gene within E. coli, Kaçar produced eight identical bacterial strains and allowed 'ancient life' to re-evolve. This chimeric bacteria composed of both modern and ancient genes survived, but grew about two times slower than its counterpart composed of only modern genes. 'The altered organism wasn’t as healthy or fit as its modern-day version, at least initially,' said Gaucher, 'and this created a perfect scenario that would allow the altered organism to adapt and become more fit as it accumulated mutations with each passing day.' The growth rate eventually increased and, after the first 500 generations, the scientists sequenced the genomes of all eight lineages to determine how the bacteria adapted. Not only did the fitness levels increase to nearly modern-day levels, but also some of the altered lineages actually became healthier than their modern counterpart."

awjourn writes "As the SEC hashes out the final rules for crowdfunding equity investments in startups, one NYC entrepreneur is jumping into an industry that popular crowdfunding sites like Kickstarter won't go anywhere near: health. His company, MedStartr, launched July 11 with six companies seeking to raise money from the crowd for their health products and services. Among them, EndoGoddess, an app diabetics can use to track their blood sugar. Even MedStartr wants to raise funding on MedStartr. But will crowdfunding fly in healthcare, and more importantly, will regulators at the FDA and SEC be on board with it?"

bricko writes with an analysis at New Scientist of recent violence by self-described anarchists against scientists or scientific establishments, including the non-fatal shooting in Genoa in May of the head of a nuclear energy company. That attack "was the latest in a series of alleged anarchist attacks on scientists and engineers, including the attempted bombing of nanotechnology labs in Switzerland and Mexico. This wave of politically motivated violence has raised the question: why do anarchists hate science? Beyond the unsubtle threat of brute force, there are deeper issues that merit attention." The "hate science" line is just a line; the author is under no illusion that there is a single conspiracy, or that all who claim the "anarchist" mantle have identical (or even similar) views of science. "Despite the recent attacks and propaganda, anarchists actually have a complex relationship with science and technology. Some leading figures from anarchist history were scientists, notably Russian biologist Peter Kropotkin. Many hacktivists are anarchists who embrace technology; fiction authors sometimes look toward a future 'technotopia' based on anarchist ideals."

wisebabo writes with the news of a forward-thinking decision handed down by the Federation Equestre Internationale (reversing an earlier ban, so it's been on their minds) to not prohibit cloned horses from competing in the events it sanctions, including the Olympics. "Of course they'll still be restricted to the equestrian events (ha ha). One wonders if they'll be allowed to do the same in say, horse or dog racing. It'll then just come down to the ability of the jockeys I guess (or training). I wonder why they don't make all Olympic athletes use the same exact 'equipment' as their competitors. That would get rid of situations like with those super efficient swimsuits that were banned. Of course they really should return to the spirit of the original Games and compete naked. That would really improve ratings! (But it would make the winter games rather hazardous.) When do you think cloning athletes will become legal?" (Note to those who wish to enter more than one event: ultra-slippery swimsuits are back).

An anonymous reader writes "Scientists successfully reversed diabetes in mice by transplanting mice human stem cells into mice in a discovery that may lead to way to finding a cure for a disease that affects 8.3 percent of the U.S. population. ... In an experiment designed to mimic human clinical conditions, researchers were able to wean diabetic mice off of insulin four months after the rodents were transplanted with human pancreatic stem cells (abstract). [They] were able to recreate the 'feedback loop' that enabled insulin levels to automatically rise or fall based on the rodents' blood glucose levels. Additionally, researchers found that the mice were able to maintain healthy blood sugar levels even after they were fed large quantities of sugar. After several months, researchers removed the transplanted cells from the mice and found that the cells had all the markings of normal insulin-producing pancreatic cells."

ananyo writes "Two anti-clotting compounds already approved for use in humans may have a surprising role in treating radiation sickness. Last year's nuclear accident in Fukushima, Japan renewed anxiety over the lack of treatments for radiation poisoning. It was long thought that the effects of exposure to high doses of radiation were instantaneous and irreversible, leading to destruction of the gut and loss of bone marrow cells, which damages blood-cell production and the immune system. The two compounds are thrombomodulin (Solulin/Recomodulin), currently approved in Japan to prevent thrombosis, and activated protein C (Xigris). Treating mice with either drug post-exposure led to an eightfold increase in key bone marrow cells needed for the production of white blood cells, and improved the survival rates of mice receiving lethal radiation doses by 40–80% (abstract). And yes, the lead author's name really is Geiger."

ananyo writes "A report presented at the 2012 BIO International Convention in Boston, Massachusetts suggests that patents do not stifle progress when they occur at early phases of research, as some have suggested. Over the past decade, increases in patents have been matched by growth in the biotech and pharmaceutical sectors in India, Brazil, Singapore and other countries with emerging economies. The strength of patent rights can be quantified in an index ranging from 0 (no patent rights) to 5 (very strong). Over time, the countries that U.S. biotech and pharmaceutical companies have invested in have moved up the IP barometer, the report (PDF) says."

Peristaltic writes "Scientists at the U.S. Department of Agriculture are trying to determine if an unexpected mutation in a popular GM grass, Tifton 85, is responsible for the sudden deaths of a small herd of cattle in Elgin, Texas three weeks ago. The grass has been used for grazing since 1992 without incident, however after a severe drought last year in Texas, the grass started producing cyanide in sufficient quantities to kill a small herd of cattle in Elgin, Texas. Testing has found the cyanide-producing grass in nearby fields as well." Update: 06/23 22:59 GMT by T : Reader Jon Cousins writes with a correction that means the headline above is inaccurate for including "GM." Tifton 85, he writes, is "absolutely not genetically modified. It's a conventionally bred hybrid."